President Donald Trump will deliver his first major speech on drug prices on April 26; a recent Medicare Payment Advisory Commission proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments; nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment to treat substance use disorder for opioids.
President Donald Trump will deliver his first major speech about drug prices on April 26, Politico reported. Based on his fiscal 2019 budget request, he could advocate for Medicare and Medicaid demonstrations to test new ways of paying for drugs on a smaller scale, like allowing some states to try negotiating drug costs in Medicaid. He is unlikely to call for the sort of actions he did when he was a candidate, like allowing the government to negotiate the cost of drugs for Medicare.
A recent Medicare Payment Advisory Commission (MedPAC) proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments (EDs) that are located within 6 miles of an on-campus hospital ED, Kaiser Health News reported. Free-standing EDs have been growing and now number more than 500. The proposal is spurred by concerns that MedPAC’s payment for services at these facilities is higher than it should be since the patients who visit them are sometimes not as severely injured or ill as those at hospital facilities.
Nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment (MAT) to treat substance use disorder for opioids—a practice that legal experts say violates the Americans with Disabilities Act, STAT reported. After hospital discharge, many patients require further nursing care. But STAT has found that many nursing facilities refuse to accept such patients, often because of stigma, gaps in training, and the widespread misconception that abstinence is superior to medications for treating addiction. Nursing home staff may be unfamiliarity with MAT. Facilities may not have a clinician on staff licensed to prescribe buprenorphine and may be unaware that the patient’s primary care doctor often can continue to provide the medicine.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More